Phase II Study of Continuous Venous Infusion of 5-Fluorouracil in Advanced Pancreatic Cancer

Tajiri, Hisao; Yoshimori, Masayoshi; Okazaki, Nobuo; Miyaji, Makoto

doi:10.1159/000226887

Cited by 28 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of PD observed in the present study (20 of 21 patients, 95%) was extremely high in comparison with those in previous phase II trials of other agents in metastatic pancreatic cancer [14, 15, 16], and the MST of 4.2 months was as short as the MST in previous studies. Furthermore, clinical responses such as improvement in KPS and/or pain were not achieved in the present UFT therapy.…”

Section: Discussioncontrasting

confidence: 54%

Phase II Study of Uracil-Tegafur in Patients with Metastatic Pancreatic Cancer

Ueno¹,

Okada²,

Okusaka³

et al. 2002

Oncology

View full text Add to dashboard Cite

Objective: Uracil-tegafur (UFT) has been reported to have a broad anti-tumor activity in a variety of malignancies including colorectal cancer and breast cancer. However, its activity in pancreatic cancer has not been fully evaluated. The aim of the present study was to evaluate the anti-tumor activity and toxicity of UFT in patients with metastatic pancreatic cancer. Methods: All patients were required to have a pathologic diagnosis of pancreatic adenocarcinoma with measurable metastatic lesions, and no prior chemotherapy. A dose of 360 mg/m²/day of UFT was administered orally until the appearance of disease progression or unacceptable toxicity. Results: Twenty-two patients were entered into this study. Of 21 patients evaluable for response, no patient achieved an objective tumor response; one showed no change, and the remaining 20 showed progressive disease. The median survival time for all patients was 4.2 (range: 0.9–9.0) months. The most common toxicities were nausea/vomiting and anorexia. Five patients (23%) had to discontinue UFT treatment because of gastrointestinal toxicity. Conclusion: This schedule of UFT did not demonstrate a significant anti-tumor activity against metastatic pancreatic cancer.

show abstract

Section: Discussioncontrasting

confidence: 54%

Phase II Study of Uracil-Tegafur in Patients with Metastatic Pancreatic Cancer

Ueno¹,

Okada²,

Okusaka³

et al. 2002

Oncology

View full text Add to dashboard Cite

show abstract

“…The subjects were 103 consecutive patients with metastatic PC who had received systemic chemotherapy at the National Cancer Center Hospital, Tokyo, Japan, between February 1984 and March 1999 [1, 2, 3](table 1). None had received any anti-cancer treatment except for pancreatectomy before chemotherapy.…”

Section: Methodsmentioning

confidence: 99%

Prognostic Factors in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Systemic Chemotherapy

Ueno¹,

Okada²,

Okusaka³

et al. 2000

Oncology

View full text Add to dashboard Cite

The aim of the present study was to determine prognostic factors in patients with metastatic pancreatic adenocarcinoma (PC) receiving systemic chemotherapy. The relationship between patient characteristics and prognosis was examined in 103 consecutive patients with metastatic PC. The overall median survival time and 1-year survival rate were 3.2 months and 5.6%, respectively. Among the 20 potential prognostic variables investigated, only three variables, a serum C-reactive protein (CRP) level of ≧5 mg/dl, the performance status of 2–3 and a serum carbohydrate antigen 19-9 (CA 19-9) level of ≧10,000 U/ml were identified as the factors independently associated with a shorter survival. A prognostic index based on the regression coefficients of these three factors was proposed to classify the patients into three groups, with good, intermediate and poor prognosis. The median survival time for these three groups was 5.2, 2.6 and 1.4 months, respectively. The findings of this study may be useful in determining treatment strategies and in designing future clinical trials of systemic chemotherapy for metastatic PC.

show abstract

“…A total of 181 cycles were delivered with a mean of 6 cycles/patient (extremes, [1][2][3][4][5][6][7][8][9][10][11][12]. There were 23 patients evaluable for response because 2 patients had an early death, 2 patients had an early progression, 1 patient was lost of follow-up, 1 patient refused to continue the treatment, and the patient with neuroendocrine tumor was excluded from the evaluation.…”

Section: Efficacymentioning

confidence: 99%

“…5-FU alone gives response rates between 0% and 20% and the median survival does not exceed 5.5 months. [3][4][5] Several combinations of 5-FU with other agent were compared with 5-FU alone. The survival advantage was always nonsignificant.…”

mentioning

confidence: 99%